ALK's Board of Directors to nominate Vincent Warnery as new member of the Board
The Board of Directors of ALK-Abelló A/S (ALKB:DC / OMX: ALK B / AKABY / AKBLF) is pleased to announce that it will nominate Vincent Warnery as an independent member of the Board of ALK-Abelló A/S at the Annual General Meeting on 13 March 2019. His election will follow the standard rules for new members of the Board, as stated in the Articles of Association of ALK-Abelló A/S.
Vincent is a member of the Board of Management at the global personal care company, Beiersdorf AG, where he is head of Selective and Pharmacy brands. He will bring to ALK considerable experience from the international consumer healthcare industry gained over three decades in roles at Sanofi, Proctor & Gamble and L’Oreal. Born in 1968, Vincent is a French citizen and has an MBA from École Supérieure des Sciences Economiques et Commerciales (ESSEC).
Full information on proposed members of the Board of Directors will be provided in the notice convening the Annual General Meeting.
For further information please contact:
Carsten Hellmann, President & CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,300 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Upcoming Life Sciences Events
- September 2019
- Munich: The Biotech & Pharma Summit: Drug Delivery & Formulation
- Brussels: The Pharma Forecasting Course
- Bangkok: Bio Investment Asia 2019